Myriad's BRACAnalyis will be used as a companion diagnostic as BioMarin develops its PARP inhibitor drug candidate for patients with advanced or recurrent tumors.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.